Last reviewed · How we verify
Intra ovarian by platelet rich plasma
Intra ovarian by platelet rich plasma is a Regenerative medicine / Autologous cell therapy Biologic drug developed by Beni-Suef University. It is currently in Phase 3 development for Diminished ovarian reserve, Premature ovarian failure / Primary ovarian insufficiency, Infertility associated with low ovarian function.
Platelet-rich plasma (PRP) injected intra-ovarian delivers growth factors and cytokines to stimulate ovarian function and improve fertility outcomes.
Platelet-rich plasma (PRP) injected intra-ovarian delivers growth factors and cytokines to stimulate ovarian function and improve fertility outcomes. Used for Diminished ovarian reserve, Premature ovarian failure / Primary ovarian insufficiency, Infertility associated with low ovarian function.
At a glance
| Generic name | Intra ovarian by platelet rich plasma |
|---|---|
| Sponsor | Beni-Suef University |
| Drug class | Regenerative medicine / Autologous cell therapy |
| Modality | Biologic |
| Therapeutic area | Reproductive Medicine / Fertility |
| Phase | Phase 3 |
Mechanism of action
PRP contains concentrated platelets and growth factors (PDGF, VEGF, FGF, IGF-1) that promote tissue regeneration and angiogenesis. When injected directly into ovarian tissue, these bioactive molecules are hypothesized to enhance ovarian reserve, improve egg quality, and restore ovarian function in women with diminished ovarian reserve or premature ovarian failure.
Approved indications
- Diminished ovarian reserve
- Premature ovarian failure / Primary ovarian insufficiency
- Infertility associated with low ovarian function
Common side effects
- Ovarian pain or discomfort
- Mild bleeding or bruising at injection site
- Infection risk
Key clinical trials
- Platelet Rich Plasma on Ovarian Reserve Parameters and Intra Cytoplasmic Sperm Injection Outcomes in Patients With Diminished Ovarian Reserve (PHASE3)
- Ovarian Rejuvenation Using Platelet Rich Plasma (PRP) & Autologous Tissue Stromal Vascular Fraction (tSVF) and Cell Enriched tSVF (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intra ovarian by platelet rich plasma CI brief — competitive landscape report
- Intra ovarian by platelet rich plasma updates RSS · CI watch RSS
- Beni-Suef University portfolio CI
Frequently asked questions about Intra ovarian by platelet rich plasma
What is Intra ovarian by platelet rich plasma?
How does Intra ovarian by platelet rich plasma work?
What is Intra ovarian by platelet rich plasma used for?
Who makes Intra ovarian by platelet rich plasma?
What drug class is Intra ovarian by platelet rich plasma in?
What development phase is Intra ovarian by platelet rich plasma in?
What are the side effects of Intra ovarian by platelet rich plasma?
Related
- Drug class: All Regenerative medicine / Autologous cell therapy drugs
- Manufacturer: Beni-Suef University — full pipeline
- Therapeutic area: All drugs in Reproductive Medicine / Fertility
- Indication: Drugs for Diminished ovarian reserve
- Indication: Drugs for Premature ovarian failure / Primary ovarian insufficiency
- Indication: Drugs for Infertility associated with low ovarian function
- Compare: Intra ovarian by platelet rich plasma vs similar drugs
- Pricing: Intra ovarian by platelet rich plasma cost, discount & access